Abemaciclib in Patients with Oligodendroglioma

Abemaciclib in Patients With Oligodendroglioma

This is a phase II, single arm, open label study looking how well a drug called abemaciclib works in patients with recurrent oligodendroglioma

Pharmaceutical medication involved
Patients and healthy individuals accepted

Drug - Abemaciclib 200 MG

Subjects will be treated with abemaciclib 200mg by mouth once every 12 hours. Dosing will be continuous and administered on a 28-day cycle

A Single-Arm, Open-label, Phase II Study Evaluating the Efficacy and Safety of Abemaciclib in Patients With Recurrent Oligodendroglioma